Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011647 | 0.81 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL15226232 | 0.71 | — | — | |
| SCHEMBL293470 | 0.68 | TBXAS1 (0.34) | NPC1ALDH1A1RAB9A | |
| SCHEMBL17397420 | 0.67 | FEN1 (0.33) | SMN1; SMN2KDM4ENPC1ALDH1A1PKM | |
| Water SCHEMBL11117585 | 0.67 | CA2 (0.42) | KDM4E | |
| Water SCHEMBL3621110 | 0.67 | CA2 (0.42) | KDM4E | |
| Water SCHEMBL6912453 | 0.67 | CA2 (0.42) | KDM4E | |
| Water SCHEMBL11479512 | 0.67 | CA2 (0.42) | KDM4E | |
| SCHEMBL14578735 | 0.67 | CYP19A1 (0.35) | SMN1; SMN2KDM4ENPC1ALDH1A1PKM | |
| SCHEMBL16050529 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294714-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Nektar Therapeutics (US) | 2018-03-21 | — | — | EP | claimed |
| WO-2016182840-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2016-11-17 | — | — | WO | claimed |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3286181-B1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10208075-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180208613-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208612-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9982000-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3294714-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Nektar Therapeutics (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3286181-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016182840-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2500/4885KDM4E 1702/4885NPC1 2134/4885 |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2288/4885KDM4E 1769/4885NPC1 2036/4885 |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2500/4885KDM4E 1702/4885NPC1 2134/4885 |
| US-20180208613-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2288/4885KDM4E 1769/4885NPC1 2036/4885 |
| US-10208075-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2288/4885KDM4E 1769/4885NPC1 2036/4885 |
| US-20180208612-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2288/4885KDM4E 1769/4885NPC1 2036/4885 |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 2288/4885KDM4E 1769/4885NPC1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.